"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Descriptor ID |
D011241
|
MeSH Number(s) |
D04.210.500.745.432.719.702
|
Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 8 | 9 |
1995 | 0 | 10 | 10 |
1996 | 1 | 8 | 9 |
1997 | 1 | 7 | 8 |
1998 | 2 | 6 | 8 |
1999 | 2 | 4 | 6 |
2000 | 1 | 8 | 9 |
2001 | 1 | 11 | 12 |
2002 | 1 | 16 | 17 |
2003 | 3 | 11 | 14 |
2004 | 1 | 6 | 7 |
2005 | 1 | 5 | 6 |
2006 | 3 | 9 | 12 |
2007 | 0 | 4 | 4 |
2008 | 2 | 16 | 18 |
2009 | 1 | 9 | 10 |
2010 | 3 | 10 | 13 |
2011 | 1 | 12 | 13 |
2012 | 2 | 14 | 16 |
2013 | 4 | 20 | 24 |
2014 | 5 | 22 | 27 |
2015 | 5 | 26 | 31 |
2016 | 3 | 19 | 22 |
2017 | 0 | 14 | 14 |
2018 | 3 | 11 | 14 |
2019 | 1 | 10 | 11 |
2020 | 2 | 19 | 21 |
2021 | 3 | 15 | 18 |
2022 | 0 | 9 | 9 |
2023 | 0 | 9 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 Dec; 64(14):2258-2268.
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.
-
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023 08 01; 41(22):3839-3850.
-
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. Oncologist. 2023 06 02; 28(6):520-530.
-
Impact of follow-up adherence on disease activity in childhood-onset systemic lupus erythematosus (cSLE). Lupus. 2023 May; 32(6):799-803.
-
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.
-
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 06 20; 41(18):3339-3351.
-
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. Int J Radiat Oncol Biol Phys. 2023 08 01; 116(5):1091-1099.
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.